News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cosmo Pharmaceuticals S.p.A.'s Rifamycin Meets Target in Diarrhea Trial
July 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, July 4 (Reuters) - Italy's Cosmo Pharmaceuticals said on Wednesday a mid- to late-stage trial of its Rifamycin drug in infectious diarrhoea had met its primary objective, boosting the biotech company's shares.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
Europe
MORE ON THIS TOPIC
Infectious disease
GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients
May 28, 2026
·
2 min read
·
Tristan Manalac
Insights
France’s biotech ecosystem: science, capital and scale
May 28, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
May 27, 2026
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
May 27, 2026
·
3 min read
·
Annalee Armstrong
